Nabla Bio

About Nabla Bio

Nabla Bio aims to transform drug development into a true design discipline by reducing trial-and-error, ensuring better medicines reach patients faster and with greater confidence. Their mission is to design safer, more precise medicines that unlock new targets and expand the understanding and treatment of disease.

Products & Services

Generative Drug Design Platform:Combines de novo drug design with large-scale, human-relevant testing to turn trial-and-error discovery into designable, engineerable success. Integrates data, AI, and dry/wet-lab systems to design medicines with desired properties like binding, developability, cellular function, and in-vivo performance.

Specialties

De Novo Antibody Design Generative Drug Design AI in Drug Development Integrated Dry/Wet-Lab Systems Human-Relevant Testing

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 26000000 MR: - FA: 26 million FAN: 26000000	D: 2024-05-14 FD: 2024-05-14	3 investors

Series A Latest

2024-05-14

$26.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Surge Biswas

Co-founder & CEO

F

Frances Anastassacos

Co-founder & President

A

Adithya Paramasivam

B

Bridget Li

A

Adam Sanford

C

Connor Blankenship

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Nabla Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised